Latent and Tertiary Syphilis: In latent syphilis, serologic evidence of infection is found despite absence of symptoms and signs of the primary and secondary stages.META-INF/MANIFEST.MFname/audet/samuel/shorttyping/ShortDictManager$BufferedStream.classname/audet/samuel/shorttyping/ShortDictManager.classname/audet/samuel. JESUS FASTENING MOFFETT SHUSTER MORTARS Garbh Keerthi (Convenor, Expert Committee in Biotechnology). Group I, II and III Introns, catalytic RNA Importance of. Blood group serology Livingstone. Scientific and Clinical Publications - Siemens Healthineers Global. Welcome to the Siemens Healthcare Laboratory Diagnostics Scientific and Clinical Publications, a compilation of peer- reviewed journal articles, clinical case studies, scientific posters and more. To retrieve technical documents and Material Safety Data Sheets (MSDS) for the entire Siemens Healthcare Diagnostics portfolio, including instruments, assays, and test kits, visit our Online Document Library. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. Alternate Text: The figure above shows the timeline of course for a patient with presumptive abortive human rabies in Texas in 2009. On February 25, 2009, an. The use of serologic tests for demonstration of specific antibody to T. Alopecia areata: An update Kolalapudi Anjaneyulu Seetharam Department of Dermatology, Venereology and Leprology, Katuri Medical College, Guntur, Andhra Pradesh, India. Novavax, Inc.'s (NVAX) CEO Stanley Erck on Q3 2. Results - Earnings Call Transcript. Novavax, Inc. At this time, all participants are in a listen- only mode. Later we will conduct a question- and- answer session and instructions will follow at that time. Andrea Flynn, Associate Director of Investor Relations. Flynn, you may begin. Andrea Flynn. Thank you, operator. This is Andrea Flynn, Associate Director of Investor Relations at Novavax. I would like to thank everyone for joining today. A press release of our earnings is currently available on our website at novavax. An audio archive of this conference call will be available on our website later today. Joining me on today. Greg Glenn; Chief Medical Officer, Dr. Louis Fries; Senior Director of Clinical Development, Dr. James Cummings; and Chief Financial Officer, Buck Phillips. Before we begin our prepared remarks, I need to remind you that we will be making forward- looking statements during this teleconference that could include financial, clinical or commercial projections. Statements relating to future financial or business performance, conditions or strategies and other financial and business related matters, including expectations regarding revenue, operating expenses, cash usage and clinical developments and anticipated milestones are forward- looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward- looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. We have a slightly different agenda for today's call. Buck will start with a quick review of the third quarter financial results, following that we will begin the Investor and Analyst portion of the call with Stan. I'll now turn the call over to Buck. Barclay Phillips. Thank you, Andrea. Good evening, everyone, and thank you for joining today's call. Today we announced financial results for the third quarter ended September 3. Summary financial statements can be found in today's earnings press release. For the third quarter of 2. This compares to a net loss of $3. The increase in net loss in the third quarter of 2. R& D expenses related to the clinical trials and development activities for our RSV F vaccine candidate along with higher employee related costs relative to the same period last year. Revenue for the quarter was $3. This 5. 0% decrease in revenue in the 2. BARDA related activities in the third quarter of 2. The decline in BARDA revenue in Q3 of 2. Bill & Melinda Gates Foundation grant of $8. The Bill & Melinda Gates Foundation revenue is directly related to the Prepare trial, our Phase 3 trial of the RSV F vaccine to protect infants via maternal immunization. As we have previously discussed, we expect an increase in Bill & Melinda Gates Foundation revenue in 2. Prepare trial. R& D expenses increased 7. The increase in R& D expenses was primarily due to the increase in activities in our ongoing RSV F vaccine clinical trials and related development activities along with higher employee related expenses which includes an increase in non- cash stock compensation expense. G& A expenses increased 5. This increase is primarily due to an increase in employee related expenses which also includes increases in non- cash stock compensation expense as well as an increase in pre- commercialization expenses. As of September 3. I will provide some detail regarding future expectations for both expenses and cash burn in my section of the investor and analyst portion of this call. This concludes my financial review of the third quarter 2. I'll now turn the call over to Stan to begin the investor and analyst presentation. Stanley Erck. Thanks all for taking the time to dial into our presentation today. As a reminder this is being webcast we do have a slide presentation. So please join us on our website to access those slides. I expect from this crowd that's on the phone to get a lot of credit for the following. I'm not going to make any reference to the presidential campaign and election results today. So, with that, we have a lot of material to cover, so let me get started. On Slide 3, I'll briefly review our agenda for this call starting out I'll provide an overview of the pipeline and path forward and then I'll introduce you to Dr. You have not met James Cummings before and he has got quite a background so I'll spend a minute doing it.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2017
Categories |